Alvotech Stock Today
| ALVO Stock | USD 12.42 0.08 0.64% |
Performance3 of 100
| Odds Of DistressOver 84
|
Alvotech is selling at 12.42 as of the 21st of November 2024; that is 0.64 percent decrease since the beginning of the trading day. The stock's open price was 12.5. Alvotech has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Alvotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of June 2022 | Category Healthcare | Classification Health Care |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. The company was founded in 2013 and is headquartered in Reykjavik, Iceland. Alvotech is traded on NASDAQ Exchange in the United States. The company has 301.94 M outstanding shares of which 79.01 K shares are presently shorted by private and institutional investors with about 0.58 trading days to cover. More on Alvotech
Moving together with Alvotech Stock
Moving against Alvotech Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Alvotech Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Health Management (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Management, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAlvotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alvotech's financial leverage. It provides some insight into what part of Alvotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alvotech (ALVO) is traded on NASDAQ Exchange in USA. It is located in 9, Rue de Bitbourg, Luxembourg City, Luxembourg, 1273 and employs 999 people. Alvotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.75 B. Alvotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 301.94 M outstanding shares of which 79.01 K shares are presently shorted by private and institutional investors with about 0.58 trading days to cover.
Alvotech currently holds about 128.44 M in cash with (312.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.52.
Check Alvotech Probability Of Bankruptcy
Ownership AllocationAlvotech holds a total of 301.94 Million outstanding shares. Alvotech shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.01 percent of Alvotech outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Alvotech Ownership Details
Alvotech Historical Income Statement
Alvotech Stock Against Markets
Alvotech Corporate Management
| Christina Siniscalchi | Interim Officer | Profile | |
| Ming Li | Chief Officer | Profile | |
| Sandra Casaca | Chief Officer | Profile | |
| RoseMarie Ohlsson | Chief Officer | Profile | |
| Anil Okay | Chief Officer | Profile | |
| Giedrius Zunda | Chief Officer | Profile | |
| Sean Gaskell | Chief Officer | Profile |
Already Invested in Alvotech?
The danger of trading Alvotech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alvotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alvotech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alvotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alvotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alvotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alvotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alvotech Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alvotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Alvotech Stock, please use our How to Invest in Alvotech guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alvotech. If investors know Alvotech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alvotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.85) | Revenue Per Share 1.283 | Quarterly Revenue Growth 43.997 | Return On Assets (0.08) |
The market value of Alvotech is measured differently than its book value, which is the value of Alvotech that is recorded on the company's balance sheet. Investors also form their own opinion of Alvotech's value that differs from its market value or its book value, called intrinsic value, which is Alvotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alvotech's market value can be influenced by many factors that don't directly affect Alvotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alvotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alvotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alvotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.